SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:oru-78926"
 

Sökning: onr:"swepub:oai:DiVA.org:oru-78926" > The association bet...

  • Burkill, SarahCentre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden; Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden (författare)

The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis

  • Artikel/kapitelEngelska2019

Förlag, utgivningsår, omfång ...

  • 2019-12-30
  • PLOS,2019
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:oru-78926
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-78926URI
  • https://doi.org/10.1371/journal.pone.0227120DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:143056542URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-76188URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:141670714URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agencies:Bayer AG Biogen Netherlands B.V.  Merck KGaA  Novartis Europharm Limited 
  • Funding Agencies:Bayer AG  Biogen  Merck KGaA  Novartis Pharma AG  
  • BACKGROUND: Interferon-beta (IFN-beta) is a commonly used treatment for multiple sclerosis (MS). Current guidelines recommend cessation of treatment during pregnancy, however the results of past studies on the safety of prenatal exposure to IFN-beta have been conflicting. A large scale study of a population of MS women is therefore warranted.OBJECTIVES: To assess whether, among those born to women with MS, infants prenatally exposed to IFN-beta show evidence of smaller size at birth relative to infants which were not prenatally exposed to any MS disease modifying drugs.METHODS: Swedish and Finnish register data was used. Births to women with MS in Sweden and Finland between 2005-2014 for which a birth measurement for weight, height, and head circumference was available were included. The exposure window was from 6 months prior to LMP to the end of pregnancy.RESULTS: In Sweden, 411 pregnancies were identified as exposed to IFN-beta during the exposure window, and 835 pregnancies were counted as unexposed to any MS DMD. The corresponding numbers for Finland were 232 and 331 respectively. Infants prenatally exposed to interferon-beta were on average 28 grams heavier (p = 0.17), 0.01 cm longer (p = 0.95), and had head circumferences 0.14 cm larger (p = 0.13) in Sweden. In Finland, infants were 50 grams lighter (p = 0.27), 0.02 cm shorter (p = 0.92) and had head circumferences 0.22 cm smaller (p = 0.15) relative to those unexposed.CONCLUSIONS: This study provides evidence that exposure to IFN-beta during pregnancy does not influence birth weight, length, or head circumference.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Vattulainen, PiaEPID research, Helsinki, Finland (författare)
  • Geissbuehler, YvonneNovartis Pharma AG, Basel, Switzerland (författare)
  • Sabido Espin, MeritxellMerck group, Darmstadt, Germany (författare)
  • Popescu, CatrinelBiogen, Maidenhead, United Kingdom,Biogen, Maidenhead, UK (författare)
  • Suzart-Woischnik, KilianaBayer AG, Berlin, Germany (författare)
  • Hillert, JanKarolinska Institutet,Karolinska Institute, Stockholm, Sweden (författare)
  • Artama, MiiaNational Institute for Health and Welfare Finland, Helsinki, Finland (författare)
  • Verkkoniemi-Ahola, AuliDepartment of Neurology, Helsinki University, Helsinki, Finland (författare)
  • Myhr, Kjell-MortenDepartment of Clinical Medicine, University of Bergen, Bergen, Norway (författare)
  • Cnattingius, SvenKarolinska Institutet,Karolinska Institute, Stockholm, Sweden (författare)
  • Korhonen, PasiEPID research, Helsinki, Finland (författare)
  • Montgomery, Scott,1961-Karolinska Institutet,Örebro universitet,Institutionen för medicinska vetenskaper,Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Epidemiology and Public Health, University College London, London, United Kingdom,Clinical Epidemiology and Biostatistics(Swepub:oru)smy (författare)
  • Bahmanyar, ShahramKarolinska Institutet,Karolinska Institute, Stockholm, Sweden (författare)
  • Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden; Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, SwedenEPID research, Helsinki, Finland (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:PLOS ONE: PLOS28:Suppl. 2, s. 371-3721932-6203
  • Ingår i:Pharmacoepidemiology and Drug Safety: PLOS28:Suppl. 2, s. 371-3721053-85691099-1557

Internetlänk

Hitta via bibliotek

  • PLOS ONE (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy